Welcome and Introduction
Prognostic and Predictive Biomarkers in Aggressive B-cell Lymphomas; Role in Treatment Selection
- Mantle-Cell Lymphoma (MCL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
Patient Selection and Treatment Sequencing; Integrating
Precision Medicine Approaches into the Current Treatment Algorithm
New and Emerging Agents and Clinical Application of New Advances in MCL and DLBCL
Case Presentations and Panel Discussions Addressing Treatment Challenges and Future Directions in MCL and DLBCL
Key Takeaways and Question and Answer Session
Date / Time
Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Jeremy S. Abramson, MD, MMSc
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Grzegorz Nowakowski, MD
Professor of Medicine and Oncology
Department of Hematology
This program will provide expert faculty perspectives on the optimal integration of new classes of agents and treatment regimens into the management of MCL and DLBCL, and contextualize the role of prognostic and predictive biomarkers for risk stratification and personalization of patient care using clinical case studies to illustrate how to utilize precision medicine approaches for the selection and sequencing of therapy to achieve optimal efficacy and safety.
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with MCL and DLBCL.
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with B‑cell lymphomas.
Upon completion of this activity, participants should be able to:
- Order and interpret molecular profiling for appropriate patients with MCL and DLBCL to guide therapy selection
- Select treatment regimens for patients with MCL and DLBCL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
- Identify patients with aggressive B-cell lymphoma who would likely benefit from enrollment on a clinical trial
- Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of MCL and DLBCL
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.